Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

Anterios Inc.72 enrolled

Overview

The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of acne.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Acne Vulgaris

Interventions

ANT-1207BIOLOGICAL

single dose application

VehicleBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of moderate to severe facial acne * 15 to 40 papules and pustules, and 5 to 50 open and/or closed comedones * no presence of nodules * female subjects must be not pregnant and non-lactating Exclusion Criteria: * presence of 1 or more nodules * use of topical steroids on the face 4 weeks prior and during the study * use of systemic corticosteroids 6 weeks prior and during the study * topical or systemic acne treatment in the 4 weeks prior to Baseline

Locations (15)

Total Skin & Beauty Dermatology Center

Birmingham, Alabama, United States

International Dermatology Research

Miami, Florida, United States

Outcomes

Primary Outcomes

Efficacy will be assessed by lesion count.

inflammatory lesion count (papules, pustules, and nodules) and non-inflammatory lesion count (open and closed comedones)

Time frame: Week 4

Secondary Outcomes

Change from Baseline in Investigator Global Assessment Score

Time frame: Week 1, 2, 4, 8, and 12

Change from Baseline in Lesion Count

Time frame: Week 1, 2, 4, 8, 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.